MICAD adds 11 agents

The Molecular Imaging and Contrast Agent Database (MICAD) has uploaded 11 agents.

The PET agents are:
  • [11C]DPA-713  and [18F]PBR06, which both targets peripheral benzodiazepine receptor (PBR), also known as translocator protein (TSPO)
  • [18F]AV-45, which targets ß-amyloid peptide
  • [18F]FB-RMSH, which targets melanocortin-1 (MC-1) receptor (MC1R)

The SPECT agents are:
  • 123I-Nicotinamide, which targets gastrin/cholecystokinin-2 receptor (CCK-2R)
  • 99mTc-HYNIC-cyclo-MG1, which targets gastrin/cholecystokinin-2 receptor (CCK-2R)

The MRI agents are:
  • Gd-DOTA-R832, which targets vascular cell adhesion molecule-1 (VCAM-1)
  • Gd-DTPA-g-R826, which targets phosphatidylserine
  • USPIO-PHO, which targets ß-amyloid peptide
  • VCAM-1-PFC-19mF which targets vascular cell adhesion molecule-1 (VCAM-1)

The optical agent is:
  • Avas12a1-IRDye800, which targets vascular endothelial growth factor receptor-2 (VEGFR-2)

The MICAD database currently lists 805 agents and is developed by the National Center for Biotechnology Information at the National Institutes of Health.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.